Literature DB >> 18372531

Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro.

M Ogasawara1, J Murata, K Ayukawa, I Saiki.   

Abstract

We investigated the effect of neuropeptides, which are vasoactive intestinal polypeptide (VIP), substance P, (SP), neuropeptide Y (NPY), neurokinin A (NKA), somatostatin (SOM), calcitonin gene-related peptide (CGRP), and leucine-enkephalin (L-ENK), on the invasion of murine Colon 26-L5 adenocarcinoma cells through a reconstituted basement membrane (Matrigel) using a Transwell cell culture chamber assay. VIP, SP, NPY, and L-ENK reduced invasive potential of tumor cells in a concentration-dependent manner, whereas SOM, CGRP, and NKA had no effect. Especially, VIP showed the most effective in inhibiting tumor invasion, and achieved 50% reduction at 10(-6) M. A similar effect by VIP was also observed in cell migration to fibronectin. VIP had no effect on the growth of tumor cells at the concentrations ranging from 10(-10) to 10(-6) M. The suppressed ability of the tumor cell motility by VIP (10(-6) M) was practically recovered by co-treatment with 2',5'-dideoxyadenosine, an adenylate cyclase inhibitor. These results indicate that VIP, among the neuropeptides used, could inhibit Matrigel invasion of Colon 26-L5 carcinoma cells through partial suppression of their motility, and the reduction was associated with an intracellular cAMP-mediated pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 18372531     DOI: 10.1016/s0304-3835(97)81762-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

2.  Neuropeptides of the VIP family inhibit glioblastoma cell invasion.

Authors:  Stéphanie Cochaud; Annie-Claire Meunier; Arnaud Monvoisin; Souheyla Bensalma; Jean-Marc Muller; Corinne Chadéneau
Journal:  J Neurooncol       Date:  2015-01-07       Impact factor: 4.130

3.  Association of genetic variants in tachykinins pathway genes with colorectal cancer risk.

Authors:  Yunxian Yu; Yifeng Pan; Mingjuan Jin; Mingwu Zhang; Shanchun Zhang; Qilong Li; Xia Jiang; Hui Liu; Jing Guo; He Liu; Kun Chen
Journal:  Int J Colorectal Dis       Date:  2012-06-26       Impact factor: 2.571

4.  Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations.

Authors:  Young-Ho Kim; Han Cheol Lee; Seon-Young Kim; Young Il Yeom; Kyung Ju Ryu; Byung-Hoon Min; Duk-Hwan Kim; Hee Jung Son; Poong-Lyul Rhee; Jae J Kim; Jong Chul Rhee; Hee Cheol Kim; Ho-Kyung Chun; William M Grady; Yong Sung Kim
Journal:  Ann Surg Oncol       Date:  2011-02-05       Impact factor: 5.344

5.  Neuropeptide Y inhibits biliary hyperplasia of cholestatic rats by paracrine and autocrine mechanisms.

Authors:  Sharon DeMorrow; Fanyin Meng; Julie Venter; Dinorah Leyva-Illades; Heather Francis; Gabriel Frampton; Hae Yong Pae; Matthew Quinn; Paolo Onori; Shannon Glaser; Kelly McDaniel; Romina Mancinelli; Eugenio Gaudio; Gianfranco Alpini; Antonio Franchitto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-05-23       Impact factor: 4.052

Review 6.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

Review 7.  Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.

Authors:  Farah J Nassar; Zahraa S Msheik; Rihab R Nasr; Sally N Temraz
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

8.  Tumor interactions with soluble factors and the nervous system.

Authors:  Melanie J Voss; Frank Entschladen
Journal:  Cell Commun Signal       Date:  2010-09-07       Impact factor: 5.712

9.  NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer.

Authors:  Lars Henrik Jensen; René Olesen; Lone Noergaard Petersen; Anders Kindberg Boysen; Rikke Fredslund Andersen; Jan Lindebjerg; Lise Nottelmann; Caroline Emilie Brenner Thomsen; Birgitte Mayland Havelund; Anders Jakobsen; Torben Frøstrup Hansen
Journal:  Cancers (Basel)       Date:  2019-10-25       Impact factor: 6.639

10.  Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.

Authors:  Jean-Pierre Roperch; Roberto Incitti; Solène Forbin; Floriane Bard; Hicham Mansour; Farida Mesli; Isabelle Baumgaertner; Francesco Brunetti; Iradj Sobhani
Journal:  BMC Cancer       Date:  2013-12-01       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.